The Nation : Cancer Drug Trials OKd
A controversial drug to treat two lethal types of cancer has won approval from the Food and Drug Administration for wider trials in humans, it was announced. An FDA spokeswoman said the agency will permit the National Cancer Institute to expand the use of interleukin-2 to a larger number of patients with advanced melanoma and kidney cancer. The treatment will be available to patients selected for participation in tests at NCI-approved cancer centers. The NCI estimates that 13,000 to 15,000 people die of advanced melanoma--skin cancer--and kidney cancer each year.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
